Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes - Concepedia

Concepedia

Publication | Closed Access

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes

10

Citations

29

References

2017

Year

William V. Tamborlane, David Polidori, Domenick Argenti, Nicholas A. Di Prospero

Pediatric Diabetes

Abstract

In pediatric T2D patients, canagliflozin 100 and 300 mg had PK and PD characteristics similar to those in adults with T2D, which is likely due to the relative maturity and increased body weight of youth affected with this disorder.

References

	Year	Citations
A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes New England Journal of Medicine	2012	941
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial William T. Cefalu, Lawrence A. Leiter, Kun‐Ho Yoon, The Lancet Metabolic SyndromeDiabetes ManagementCanagliflozin Versus GlimepirideHealth SciencesInsulin Management	2013	718
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Kaj Stenlöf, William T. Cefalu, Kyung‐Ah Kim, Diabetes Obesity and Metabolism	2012	606
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Fernando J. Lavalle‐González, Andrzej Januszewicz, Jaime A. Davidson, Diabetologia	2013	488
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease J.‐F. Yale, George L. Bakris, Bertrand Cariou, Diabetes Obesity and Metabolism	2013	480
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock, Diabetes Care	2013	473
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes Julio Rosenstock, Naresh Aggarwal, David Polidori, Diabetes Care	2012	415
Effect of Metformin in Pediatric Patients With Type 2 Diabetes Kenneth L. Jones, Silva Arslanian, Valentina A. Peterokova, Diabetes Care	2002	393
Assessment and monitoring of glycemic control in children and adolescents with diabetes Marian Rewers, Kubendran Pillay, Carine de Beaufort, Pediatric Diabetes	2014	315
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial John Wilding, G. Charpentier, Priscilla Hollander, International Journal of Clinical Practice	2013	314

Page 1